New insight into unexpected bone formation by denosumab

Epidemiology and outcomes of osteoporotic fractures

Cummings, S. R., & Melton, L. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08657-9 · Cited by 3,821 · see citing works

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489 · see citing works

Osteoporosis

Compston, J. E., McClung, M. R., & Leslie, W. D. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32112-3 · Cited by 2,449 · see citing works

TGF-β1–induced migration of bone mesenchymal stem cells couples bone resorption with formation

Tang, Y., Wu, X., Lei, W., Pang, L., Wan, C., Shi, Z., Zhao, L., Nagy, T. R., Peng, X., Hu, J., et al. (2009) · Nature Medicine · doi:10.1038/nm.1979 · Cited by 1,165 · see citing works

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

Bone, H. G., Wagman, R. B., Brandi, M. L., Brown, J. P., Chapurlat, R., Cummings, S. R., Czerwiński, E., Fahrleitner-Pammer, A., Kendler, D. L., Lippuner, K., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30138-9 · Cited by 996 · see citing works

Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells

Xian, L., Wu, X., Pang, L., Lou, M., Rosen, C. J., Qiu, T., Crane, J., Frassica, F., Zhang, L., Rodriguez, J. P., et al. (2012) · Nature Medicine · doi:10.1038/nm.2793 · Cited by 631 · see citing works

Coupling of bone resorption and formation by RANKL reverse signalling

Ikebuchi, Y., Aoki, S., Honma, M., Hayashi, M., Sugamori, Y., Khan, M., Kariya, Y., Kato, G., Tabata, Y., Penninger, J. M., et al. (2018) · Nature · doi:10.1038/s41586-018-0482-7 · Cited by 557 · see citing works

Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update

Shoback, D., Rosen, C. J., Black, D. M., Cheung, A. M., Murad, M. H., & Eastell, R. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa048 · Cited by 452 · see citing works

Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension

Papapoulos, S. E., Chapurlat, R. D., Libanati, C. R., Brandi, M. L., Brown, J. P., Czerwinski, E. J., Krieg, M.-A., Man, Z., Mellström, D., Radominski, S., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1479 · Cited by 345 · see citing works

Subperiosteal Expansion and Cortical Remodeling of the Human Femur and Tibia with Aging

Ruff, C. B., & Hayes, W. C. (1982) · Science · doi:10.1126/science.7112107 · Cited by 318 · see citing works

RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass

Bonnet, N., Bourgoin, L., Biver, E., Douni, E., & Ferrari, S. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125915 · Cited by 314 · see citing works

骨粗鬆症【JST・京大機械翻訳】

Compston Juliet, E., McClung Michael, R., & Leslie William, D. (2019) · The Lancet · Cited by 261 · see citing works

mTOR signaling in skeletal development and disease

Chen, J., & Long, F. (2018) · Bone Research · doi:10.1038/s41413-017-0004-5 · Cited by 257 · see citing works

Bone Modeling and Remodeling

Seeman, E. (2009) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v19.i3.40 · Cited by 242 · see citing works

Fracture prediction, imaging and screening in osteoporosis

Fuggle, N. R., Curtis, E. M., Ward, K. A., Harvey, N. C., Dennison, E. M., & Cooper, C. C. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0220-8 · Cited by 184 · see citing works

RANKL signaling in bone marrow mesenchymal stem cells negatively regulates osteoblastic bone formation

Chen, X., Zhi, X., Wang, J., & Su, J. (2018) · Bone Research · doi:10.1038/s41413-018-0035-6 · Cited by 154 · see citing works

Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial

Takeuchi, T., Tanaka, Y., Soen, S., Yamanaka, H., Yoneda, T., Tanaka, S., Nitta, T., Okubo, N., Genant, H. K., & van der Heijde, D. M. F. M. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214827 · Cited by 141 · see citing works

Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody

von Moos, R., Costa, L., González‐Suárez, E., Terpos, E., Niepel, D., & Body, J. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.05.003 · Cited by 138 · see citing works

Sustained Modeling-Based Bone Formation During Adulthood in Cynomolgus Monkeys May Contribute to Continuous BMD Gains With Denosumab

Ominsky, M. S., Libanati, C. R., Niu, Q., Boyce, R. W., Kostenuik, P. J., Wagman, R. B., Baron, R., & Dempster, D. W. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2480 · Cited by 123 · see citing works

The YAP/TAZ transcriptional co-activators have opposing effects at different stages of osteoblast differentiation

Xiong, J., Almeida, M., & O’Brien, C. A. (2018) · Bone · doi:10.1016/j.bone.2018.04.001 · Cited by 115 · see citing works

Stimulation of Bone Formation in Cortical Bone of Mice Treated with a Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-binding Peptide That Possesses Osteoclastogenesis Inhibitory Activity

Furuya, Y., Inagaki, A., Khan, M., Mori, K., Penninger, J. M., Nakamura, M., Udagawa, N., Aoki, K., Ohya, K., Uchida, K., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.426080 · Cited by 77 · see citing works

Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study

Dempster, D. W., Zhou, H., Recker, R. R., Brown, J. P., Recknor, C. P., Lewiecki, E. M., Miller, P. D., Rao, S. D., Kendler, D. L., Lindsay, R., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-4181 · Cited by 68 · see citing works

Longitudinal Effects of Teriparatide or Zoledronic Acid on Bone Modeling- and Remodeling-Based Formation in the SHOTZ Study

Dempster, D. W., Zhou, H., Ruff, V. A., Melby, T. E., Alam, J., & Taylor, K. A. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3350 · Cited by 57 · see citing works

RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells

Wittrant, Y., Lamoureux, F., Mori, K., Riet, A., Kamijo, A., Heymann, D., & Rédiní, F. (2006) · International Journal of Oncology · doi:10.3892/ijo.28.1.261 · Cited by 53 · see citing works

Dendritic-cell-derived osteoclasts: a new game changer in bone-resorption-associated diseases

Lapérine, O., Blin‐Wakkach, C., Guicheux, J., Beck-Cormier, S., & Lesclous, P. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.022 · Cited by 52 · see citing works

Modeling-Based Bone Formation in the Human Femoral Neck in Subjects Treated With Denosumab

Dempster, D. W., Chines, A. A., Bostrom, M. P., Nieves, J. W., Zhou, H., Chen, L., Pannacciulli, N., Wagman, R. B., & Cosman, F. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4006 · Cited by 47 · see citing works

Unexpected Bone Formation Produced by RANKL Blockade

Portal-Núñez, S., Mediero, A., Esbrit, P., Sánchez-Pernaute, O., Largo, R., & Herrero-Beaumont, G. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.06.003 · Cited by 32 · see citing works

Effects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis

Törring, O. (2015) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x15579189 · Cited by 30 · see citing works

Effects of long term treatment with high doses of odanacatib on bone mass, bone strength, and remodeling/modeling in newly ovariectomized monkeys

Duong, L. T., Pickarski, M., Cusick, T. E., Chen, C. M., Zhuo, Y., Scott, K., Samadfam, R., Smith, S. Y., & Pennypacker, B. L. (2016) · Bone · doi:10.1016/j.bone.2016.04.024 · Cited by 20 · see citing works

Healthier bones and less recurrence with denosumab

Romero, D. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0197-1 · Cited by 2 · see citing works

Denosumab in early-stage breast cancer

Brandão, M., Debiasi, M., & de Azambuja, E. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30146-9 · Cited by 2 · see citing works

Subchondral bone microenvironment in osteoarthritis and pain

Hu, Y., Chen, X., Wang, S., Jing, Y., & Su, J. (2021) · Bone Research · doi:10.1038/s41413-021-00147-z · Cited by 577 · see citing works

Bone remodeling: an operational process ensuring survival and bone mechanical competence

Bolamperti, S., Villa, I., & Rubinacci, A. (2022) · Bone Research · doi:10.1038/s41413-022-00219-8 · Cited by 482 · see citing works

Exosome-guided bone targeted delivery of Antagomir-188 as an anabolic therapy for bone loss

Hu, Y., Li, X., Zhang, Q., Gu, Z., Luo, Y., Guo, J., Wang, X., Jing, Y., Chen, X., & Su, J. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.02.014 · Cited by 210 · see citing works

Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), and the International Osteoporosis Foundation (IOF) under the auspices of WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging

Shevroja, E., Reginster, J., Lamy, O., Al‐Daghri, N. M., Chandran, M., Demoux, A., Kohlmeier, L., Lecart, M.-P., Messina, D., Camargos, B. M., et al. (2023) · Osteoporosis International · doi:10.1007/s00198-023-06817-4 · Cited by 208 · see citing works

Exosome-based bone-targeting drug delivery alleviates impaired osteoblastic bone formation and bone loss in inflammatory bowel diseases

Guo, J., Wang, F., Hu, Y., Luo, Y., Wei, Y., Xu, K., Zhang, H., Liu, H., Bo, L., Lv, S., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100881 · Cited by 182 · see citing works

Bone‐Targeted Exosomes: Strategies and Applications

Wang, J., Li, X., Wang, S., Cui, J., Ren, X., & Su, J. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202203361 · Cited by 88 · see citing works

The “Three in One” Bone Repair Strategy for Osteoporotic Fractures

Chen, X., Hu, Y., Geng, Z., & Su, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.910602 · Cited by 63 · see citing works

Construction of Local Drug Delivery System on Titanium-Based Implants to Improve Osseointegration

Meng, F., Yin, Z., Ren, X., Geng, Z., & Su, J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051069 · Cited by 52 · see citing works

The Effect of Acknowledged and Novel Anti-Rheumatic Therapies on Periodontal Tissues—A Narrative Review

Mârțu, M.-A., Maftei, G.-A., Luchian, I. A., Ștefănescu, O. M., Scutariu, M. M., & Solomon, S. M. (2021) · Pharmaceuticals · doi:10.3390/ph14121209 · Cited by 33 · see citing works

A selected small molecule prevents inflammatory osteolysis through restraining osteoclastogenesis by modulating PTEN activity

Chen, Y., Hu, W., Wang, Y., Li, Y., Li, X., Li, H., Tang, Y. M., Zhang, L., Dong, Y., Yang, X., et al. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.240 · Cited by 20 · see citing works

The Effects of Receptor Activator of NF-κB Ligand-Binding Peptides on Bone Resorption and Bone Formation

Rashed, F. M., Kamijo, S., Shimizu, Y., Hirohashi, Y., Khan, M., Sugamori, Y., Murali, R., & Aoki, K. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.648084 · Cited by 14 · see citing works

Angiopoietin 1 Relieves Osteolysis by Promoting Macrophage Mitophagy Through the TBK1-SQSTM1 Pathway to Inhibit AIM2 Inflammasome-Mediated Pyroptosis

Yin, J., Lai, P., Zhu, L., & Ma, J. (2024) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-024-04961-z · Cited by 5 · see citing works

Liposomes: An Intelligent Drug Delivery System for Translational Applications in Bone Biomedicine

Feng, W., Xue, Y., Chang, B., Wang, C., Liu, R., Zhou, Y., Zhan, L., Gao, Q., & Fan, B. (2026) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.70089 · Cited by 1 · see citing works

Unexpected Bone Formation Produced by RANKL Blockade

Portal-Núñez, S., Mediero, A., Esbrit, P., Sánchez-Pernaute, O., Largo, R., & Herrero-Beaumont, G. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.06.003 · Cited by 32 · see citing works

The mechanism of anti-RANKL antibody in the treatment of metabolic bone diseases including osteoporosis — possible applications of anti-RANKL antibody to the treatment of cancer patients

Yasuda, H. (2019) · Folia Pharmacologica Japonica · doi:10.1254/fpj.153.11 · Cited by 6 · see citing works

Denosumab

Bartl, R., & Bärtl, C. (2026) · Springer eBooks · doi:10.1007/978-3-032-21885-8_25

Anti-RANKL antibody was approved for the treatment of osteoporosis in Japan

Yasuda, H. (2013) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.36.209 · Cited by 3 · see citing works

Other Drugs in Osteoporosis

Bartl, R., & Bärtl, C. (2016) · Springer eBooks · doi:10.1007/978-3-319-29182-6_30